# **HIV-1** drug resistance in people on dolutegravir-based ART:

# Collaborative analysis of cohort studies

Tom Loosli<sup>1,2</sup>, Stefanie Hossmann<sup>3</sup>, Suzanne M. Ingle<sup>4</sup>, Hajra Okhai<sup>5</sup>, Katharina Kusejko<sup>1,2</sup>, Johannes Mouton<sup>6</sup>, Pantxika Bellecave<sup>7</sup>, Ard van Sighem<sup>8</sup>, Melanie Stecher<sup>9,10</sup>, Antonella d'Arminio Monforte<sup>11</sup>, M. John Gill<sup>12,13</sup>, Caroline A. Sabin<sup>5</sup>, Gary Maartens<sup>6</sup>, Huldrych F. Günthard<sup>1,2</sup>, Jonathan A. C. Sterne<sup>4</sup>, Richard Lessells<sup>15,16,\*</sup>, Matthias Egger<sup>3,4,16,\*</sup>, Roger Kouyos<sup>1,2,\*</sup>

# \* Authors contributed equally

1

2

3

4

5

6

7

8

11

18 19

20

21

22

23 24

25

26

27

28 29

30

- 9 1. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
  - 2. Institute of Medical Virology, University of Zurich, Zurich, Switzerland
- 12 3. Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland
- 4. Population Health Sciences, Bristol Medical School, University of Bristol, UK
- 14 5. Institute for Global Health, University College London, UK
- Department of Medicine, University of Cape Town, Cape Town, South Africa
- 16 7. Virology laboratory, University Hospital Bordeaux, Bordeaux, France
- 17 8. Stichting hiv monitoring, Amsterdam, the Netherlands
  - 9. German Center for Infection Research (DZIF), Partner-Site Cologne-Bonn, Cologne, Germany
    - 10. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf
    - 11. Italian Cohort Naive Antiretrovirals, (ICONA) L'Azienda Socio Sanitaria Territoriale (ASST) Santi Paolo e Carlo, Milano, Italy
    - 12. Southern Alberta Clinic, Calgary, AB, Canada
    - 13. Department of Medicine, University of Calgary, Calgary, AB, Canada
    - 14. KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa
      - 15. Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa
    - 16. Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- 31 Correspondence to: Prof Matthias Egger MD; matthias.egger@ispm.unibe.ch
- Word counts: Abstract 293 words, research in context 432 words, main text 3281 words, 2 tables, 4 figures, 39 references, online appendix with 12 pages.

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Summary Background: The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) in first- and second-line antiretroviral therapy (ART) may facilitate emerging resistance. We combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for DTG resistance. Methods: Eight cohorts from Canada, Europe, and South Africa contributed data on individuals with genotypic resistance testing on DTG-based ART. Resistance levels were categorised using the Stanford algorithm. We identified risk factors for resistance using mixed-effects ordinal logistic regression models. Results: We included 750 people with genotypic resistance testing on DTG-based ART between 2013 and 2022. Most had HIV subtype B (N=444, 59.2%) and were treatment-experienced; 134 (17.9%) were on DTG dual and 19 (2.5%) on DTG monotherapy. INSTI DRMs were detected in 100 (13.3%) individuals; 21 (2.8%) had more than one mutation. Most (N=713, 95.1%) were susceptible to DTG, 8 (1.1%) had potential-low, 5 (0.7%) low, 18 (2.4%) intermediate and 6 (0.8%) high-level DTG resistance. The risk of DTG resistance was higher on DTG monotherapy (adjusted odds ratio (aOR) 37.25, 95% CI 11.17 to 124.2) and DTG lamivudine dual therapy (aOR 6.59, 95% CI 1.70 to 25.55) compared to combination ART, and higher in the presence of potential-low/low (aOR 4.62, 95% CI 1.24 to 17.2) or intermediate/high-level (aOR 7.01, 95% CI 2.52 to 19.48) nucleoside reverse transcriptase inhibitors (NRTI) resistance. Viral load on DTG showed a trend towards increased DTG resistance (aOR 1.42, 95% CI 0.92 to 2.19 per standard deviation of  $log_{10}$  area under the viral load curve). Interpretation: Among people experiencing virological failure on DTG-based ART, INSTI DRMs were uncommon, and DTG resistance was rare. DTG monotherapy and NRTI resistance substantially increased the risk for DTG resistance, which is of concern, notably in resource-limited settings.

Funding: US National Institutes of Health, Swiss National Science Foundation.

# **Research in context**

#### Evidence before this study

We searched SCOPUS on 20 March 2023 for all publications from inception using the terms "dolutegravir" or "DTG", "resistant" or "resistance", and "HIV". The available evidence on resistance evolution in people living with HIV (PLHIV) with virological failure on DTG-based ART is limited. Most studies assessed the efficacy of DTG-based regimens in clinical studies and reported drug resistance in individuals experiencing virological failure as a secondary objective or reported single or multiple cases of patients developing resistance on DTG-based ART. Clinical trials such as the NADIA trial showed a high degree of viral suppression even in people with NRTI resistance. Consequently, previous analyses included only a small number of people experiencing failure on DTG; the SINGLE trial with 39 people with virologic failure on DTG was the largest. The highest number of individuals with DTG resistance was nine study participants in the NADIA trial. There is evidence that DTG resistance in PLHIV on a DTG monotherapy may be more likely. Other studies suggest that HIV subtype and mutations acquired during a first-generation INSTI-based regimen might affect the risk of DTG resistance.

#### Added value of this study

To our knowledge, this is the first study systematically investigating resistance in PLHIV experiencing virologic failure on DTG-based ART using a multi-cohort collaboration design reflecting real-world routine care. We collected genotypic resistance tests and clinical data from eight observational HIV cohorts. This resulted in a large dataset of PLHIV experiencing virologic failure on a DTG regimen (over 700 individuals). It allowed a robust assessment of drug resistance mutations and risk factors for DTG resistance. Cross-resistance of first-generation INSTIs does not appear to explain the mutation patterns in HIV-infected individuals who experience virological failure on DTG-based ART regimens. PLHIV who received DTG monotherapy or DTG lamivudine dual therapy and those infected with non-B subtypes were more likely to develop resistance. Resistance to NRTIs was a major risk factor for DTG resistance, indicating that PLHIV receiving functional monotherapy are more likely to develop DTG resistance.

### Implications of all the available evidence

HIV drug resistance is a significant threat to the sustainability of current and future antiretroviral therapy for combating the ongoing HIV pandemic. Our collaborative analysis shows that cases of DTG resistance are so far rare but not negligible. Given the global DTG roll-out, this might lead to increased frequencies and transmission of DTG resistance, particularly in PLHIV with resistance to

- 93 NRTIs. While the evidence regarding subtype differences is tentative, it indicates that non-B
- 94 subtypes, which are most relevant for the global roll-out of DTG, might be associated with an
- 95 increased risk of resistance.

Introduction

The integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) was approved in 2013 in the United States and shortly afterwards in the European Union to treat HIV infection. In 2019, the World Health Organization (WHO) recommended DTG as the preferred drug for first-line and second-line antiretroviral therapy (ART) in all populations, including pregnant women and those of childbearing age. Since then, DTG-based ART was rolled out globally, with about 100 countries including DTG in their treatment guidelines by mid 2020.

DTG has a high genetic barrier to resistance, 3,4 and relatively few people living with HIV (PLHIV) are so far known to have developed resistance. 5-7 The mutations leading to DTG resistance may differ

between HIV subtypes. In INSTI-naïve PLHIV, DTG resistance is mainly associated with the R263K mutation,<sup>8,9</sup> which was observed in three cases of DTG resistance in the NADIA trial.<sup>10</sup> The N155H mutation was present in two individuals with subtype A and C in the SAILING trial,<sup>11</sup> while the G118R mutation appears to be facilitated by a natural polymorphism in subtype C.<sup>12</sup> In a recent study in

Ethiopia, the Q148H/K/R mutation was found to be less prevalent in subtype C.<sup>13</sup> Pre-existing mutations, such as those acquired during a first-generation INSTI regimen, may directly confer

resistance to DTG or affect the accumulation of additional mutations. 14,15

The risk factors and the mutational patterns that confer resistance to DTG in vivo are less well established than for older antiretroviral drugs. <sup>16</sup> The widespread use of DTG in resource-limited settings, where ART regimens are highly standardised, drugs are recycled, access to adherence support, viral load and resistance testing is limited, may facilitate the emergence of resistance. We combined data from European, North American, and South African cohorts to identify risk factors for DTG resistance and to examine the patterns of resistance mutations across different HIV subtypes.

## Methods

### Data sources

We pooled data from eight HIV cohorts, including six European, one Canadian, and one South African cohort: the AIDS Therapy Evaluation in the Netherlands cohort (ATHENA),<sup>17</sup> the Agence Nationale de la Recherche sur le SIDA et les hépatites virales (ANRS CO3), Aquitaine Cohort,<sup>18</sup> the Italian Cohort of Antiretroviral-Naïve Patients (ICONA),<sup>19</sup> the Köln/Bonn Cohort (CBC), Germany,<sup>20</sup> the UK Collaborative HIV Cohort (UK CHIC) Study (and linked UK HIV Drug Resistance Database (UKHDRD)),<sup>21</sup> the Swiss HIV Cohort Study (SHCS),<sup>22</sup> the South Alberta Clinic Cohort (SAC), Canada,<sup>23</sup> and the South African Aid for AIDS (AfA) cohort.<sup>24</sup> The European and North-American cohorts (apart from UK CHIC) participate in the ART Cohort Collaboration (ART-CC)<sup>25</sup> and

130

131

132

133

134

135

136

137

138

139

140

141142

143

144

145

146

147

148

149

150

151 152

153

154

155

156

157

158

159

provides further details.

AfA in the International epidemiology Databases to Evaluate AIDS (IeDEA).<sup>26</sup> The clinical data were provided by the data centres of the two cohort collaborations, and the genotypic data by the cohorts. Inclusion criteria Participants who underwent genotypic resistance testing from plasma HIV-1 RNA covering the integrase gene between two weeks after starting and up to two months after stopping any DTGbased regimen were eligible. In the case of multiple genotypic resistance tests, the latest was considered. Participants with unknown dates of initiation of DTG-based ART were excluded. The analysis of risk factors for DTG resistance was restricted to individuals with at least one year of follow-up. **HIV drug resistance** We defined two HIV drug resistance outcomes: the level of resistance to DTG and the presence of known drug resistance mutations (DRMs). The Stanford HIV Database version 9.0 and the Stanford HIVdb algorithm<sup>27</sup> were used to categorise drug resistance levels as susceptible (score below 10), potential low (10-14), low (15-29), intermediate (30-59) or high (>60). The same approach was used to assess resistance to all other antiretroviral drugs, whereby drug resistance to tenofovir alafenamide (not covered by the Stanford algorithm) was considered equal to tenofovir resistance. Resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) was calculated as the median of the scores for efavirenz, etravirine, nevirapine, and rilpivirine. Resistance to nucleoside reverse transcriptase inbibitors (NRTIs) was calculated as the median of abacavir, zidovudine, emtricitabine/lamivudine, and tenofovir scores (see sensitivity analyses for alternative definitions). **HIV** subtyping We determined HIV subtypes from the integrase gene using COMET (COntext-based Modeling for Expeditious Typing)<sup>28</sup> and REGA.<sup>29</sup> If REGA and COMET output differed, the subtype with higher support was assigned. As nucleotide sequecnes were not available for AfA, we used subtype information as provided by the cohort based on reverse transcriptase (RT) and protease. For Aguitaine, information on subtype was used where available, and otherwise considered as unknown. The Aquitaine subtypes were characterised locally using Blast analysis on Smartgene HIV module on two genes at least. In the analysis, we grouped HIV subtypes other than the four most common subtypes (B, C, A, G) as other (subtypes F, AD, AE, D, 06 CPX, 18 CPX, unknown). The appendix (p 1)

Definitions

Individuals who were prescribed raltegravir or elvitegravir before starting the DTG-based regimen were considered exposed to first-generation INSTIs. Viral load testing frequency was calculated for individuals with more than one year of follow-up before the Genotypic Resistance Test (GRT). We quantified HIV viral load as the area under the curve (AUC) of the log<sub>10</sub>-transformed viral load measurements from DTG initiation to the GRT sample date. To account for differences in detection limits, we set any viral load measurement below 50 to 0 copies/ml. For individuals who initiated ART with the DTG-based regimen, we excluded high viral loads at ART initiation by setting measurements within the first 180 days from the first HIV RNA measurement to 0. Time on DTG-based ART was calculated in years from DTG initiation to GRT. The ART regimen at GRT was considered the regimen an individual was taking 14 days before the test. If available, GRT results from earlier time points were used to assess prior NRTI resistance.

#### Statistical analysis

We used descriptive statistics to present the characteristics of the study population and the different INSTI drug-resistance mutations. A negative binomial generalised linear model, adjusting for HIV subtype, exposure to first-generation INSTIs, and sex, was used to analyse the number of major and accessory INSTI drug-resistance mutations. We used ordinal logistic regression to identify risk factors for developing resistance, including cohort as a random effect. We considered variables based on availability and clinical relevance. We included sex, age at initiation and time on the DTG-based regimen, HIV subtype, type of ART (combination ART based on three drugs or more, DTG lamivudine dual therapy, other lamivudine dualtherapy, or monotherapy), exposure to first-generation INSTIs, HIV viral load, viral load testing frequency, and resistance to NRTIs. The missing data was included as a separate category if the sequencing did not cover the RT. All analyses were performed in R, version 4.0.5.

#### Sensitivity analyses

We performed several sensitivity analyses. First, we replaced the NRTI resistance variable with the presence or absence of the M184V/I mutation (sensitivity analysis S1). Further, we performed logistic regression using the same covariables as in the main risk factor analysis, using susceptible versus any DTG resistance as the outcome (S2). We repeated the risk factor analyses excluding study participants where RT was not sequenced (S3). Given the widespread use of tenofovir-lamivudine-dolutegravir (TLD), we restricted the analysis of NRTIs to tenofovir and lamivudine and used the

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

higher resistance level of the two to quantify NRTI resistance (S4). In the subset of people on a DTG + 2 NRTI regimen, we calculated NRTI resistance specific to the two NRTIs used in each participant (S5). The main analysis could not assess whether NRTI and NNRTI resistance mutations pre-existed or were acquired on DTG. Sensitivity analysis S6 restricted the study population to participants with available GRTs before experiencing virological failure on the DTG-containing regimen. Role of the funding source The funders of the study did not participate in the study design, data collection, data analysis, data interpretation, and writing of the report. The corresponding author had full access to the data of this study and had the final responsibility for the decision to submit for publication. Results A total of 750 people met the eligibility criteria and were included in the analysis of mutations conferring resistance to DTG; 677 (90.3%) had more than one year of follow-up since starting the DTG-based regimen and were included in the analysis of risk factors for DTG resistance. Characteristics of the study population The study participants included in the two analyses were similar (Table 1): most participants were men living with HIV subtype B who were on combination ART with three or more antiretroviral drugs. The median year of starting DTG was 2016. People were on DTG for a median of 16 and 1.7 years, and the median AUC of log10 viral load (copies/mL) accumulated during this period was around 3. The first GRT was performed in May 2013, and the last in January 2022. About a third of participants had previously been exposed to first-generation INSTIs. A total of 193 people did not have a CD4 measurement within a year of the GRT, 25 did not have any recorded HIV RNA measurements before the GRT, and in 74 people sequencing did not cover RT. The appendix (p 1) provides further details on the ART regimens. **INSTI** mutations and DTG resistance At least one major or accessory INSTI DRM was found in 100 (13.3%) of the 750 study participants; 21 (2.8%) had more than one mutation. Most (713; 95.1%) study participants were fully susceptible to DTG, with potential low, low, intermediate, and high levels of DTG resistance being observed in 8 (1.1%), 5 (0.7%), 18 (2.4%) and 6 (0.8%), respectively (Figure 1). The INSTI resistance mutations observed in all enrolled people with a DTG resistance score > 0 are shown in the appendix (p 2). The most common major INSTI DRM was R263K (N=11), which only once occurred with another major INSTI DRM (appendix p 2). Other common major mutations included the G140 (N = 10), N155

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

(N = 9), Q148 (N = 8), and the E138 mutation (N = 7). The G118R mutation, which has the strongest impact on susceptibility to DTG, was only observed three times. Among accessory DRMs, E157 (N = 25) and T97 (N = 20) were the most common. The distribution of INSTI resistance mutations was similar in people previously exposed to first-generation INSTIs and those not exposed (Figure 2). There was no statistically significant association of specific DRMs with first-generation INSTI experience. For HIV subtype, we found a significant association for the accessory INSTI DRM T97 (see appendix p 3). This DRM occurred in 6 of 56 (10.7%) people with HIV subtype A, 4 of 42 (9.5%) people with subtype G, 7 of 444 (1.6%) people with subtype B, and 0 of 71 people with HIV subtype The results from the negative binomial model of the number of mutations showed little evidence of a difference between HIV subtypes. The number of INSTI DRMs was higher in first-generation INSTIexposed people (adjusted RR 1.59, 95% CI 1.03 to 2.48) (Figure 3). This association became even stronger when considering the number of major INSTI DRMs (adjusted RR 2 60, 95% CI 1 30 to 5 31) (see appendix p 4 for further details). The prevalence of resistance mutations (low, intermediate or high) to NRTIs and NNRTIs was substantially higher in the presence of DTG resistance (Table 2). Among GRTs with coverage of the RT, the prevalence of at least low level NRTI resistance was 10·1% overall (66 of 654) but 31·8% (7 of 22) among those with DTG resistance. The corresponding figures for NNRTI resistance were 12.8% (84 of 654) and 50% (11 of 22). Risk factors for DTG resistance The risk of DTG resistance was higher on DTG monotherapy compared to combination ART with >3 drugs (adjusted odds ratio [aOR] 37·25, 95% CI 11·17 to 124·2) and for DTG lamivudine dual regimen (aOR 6.59, 95% CI 1.70 to 25.55) (Figure 4). The risk of resistance was also increased in the presence of a potential low/low level of NRTI resistance (aOR 4.62, 95% CI 1.24 to 17.2) or intermediate/high level (aOR 7.01, 95% CI 2.52 to 19.48), compared to no NRTI resistance. Non-B HIV subtypes tended towards higher resistance levels, mainly driven by subtype A (aOR 3·27, 95% CI 0.90 to 11.87) (appendix p 5). There was a trend for an association of viral load with DTG resistance (aOR 1.42, 95% CI 0.92 to 2.19 per standard deviation of the log<sub>10</sub> virus load area under the curve). Sensitivity analyses The results of the risk factor analyses were similar when replacing the NRTI resistance variable with the M184V/I mutation (sensitivity analysis S1, appendix p7) or when analysing susceptible versus

any DTG resistance as the outcome in a logistic regression (S2, appendix p 8). The exclusion of 64 individuals with missing RT sequences allowed the inclusion of both NRTI and NNRTI resistance in the model. The results for NRTI resistance were similar, and intermediate/high-level NNRTI resistance was also associated with DTG resistance (adjusted OR 4·07, 95% CI 1·07 – 15·5) (S3, appendix p 9). The analysis restricted to lamivudine and tenofovir (S4, appendix p 10) confirmed that DTG resistance was associated with potential low/low and intermediate/high-level resistance to these NRTI drugs. Similarly, when restricting the analysis to people on a DTG regimen with two NRTI backbones, we found similar results for the specific NRTIs (S5, appendix p 11). Finally, in the last sensitivity analysis (S6) we used data on pre-existing NRTI resistance and found that DTG resistance was associated with prior intermediate/high NRTI resistance (appendix p 12).

# **Discussion**

 In this collaborative analysis of eight large cohort studies, we identified INSTI DRMs in 100 of 750 (13·3%) PLHIV who experienced virologic failure on DTG-based ART, and resistance to DTG according to the Stanford algorithm was present in 37 (4·9%) individuals. DTG resistance was associated with DTG monotherapy, lamivudine DTG dual therapy, resistance to RT inhibitors, non-B subtype, and HIV viral replication but not with previous first-generation INSTI exposure. A wide range of INSTI DRMs was present. The polymorphic accessory INSTI DRM T97A was detected more frequently in subtypes A and G (compared to subtypes B and C), consistent with previously reported data. The major INSTI DRMs at positions 140 and 148 were detected in 5 out of 6 people with high-level DTG resistance, all of whom were first-generation INSTI experienced.

strongly associated with DTG resistance in our study. The complete sequence analysis, which allowed us to distinguish between NRTI and NNRTI resistance, suggests that the association may be mediated via NRTI resistance. It was robust when considering only 3TC and TDF resistance in a sensitivity analysis. As the main analysis was cross-sectional, it did not allow the determination of the timing of NRTI resistance relative to DTG resistance. However, an additional analysis in people with prior resistance tests suggests that NRTI resistance may often have predated DTG resistance. These results indicate that resistance to NRTI backbone drugs from previous regimens may have promoted the emergence of DTG resistance. However, its also possible that prior NRTI resistance reflects adherence issues, which may facilitate the emergence of DTG resistance.

The strong associations of DTG resistance with DTG monotherapy and NRTI resistance are consistent with previous findings, <sup>10,31,32</sup> but appear to contradict the results from the NADIA trial, which found no evidence that the efficacy of DTG-based ART is affected by resistance to the NRTI backbone. <sup>10</sup>

no evidence that the efficacy of DTG-based ART is affected by resistance to the NRTI backbone.\*

289

290

291

292293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311312

313

314 315

316317

318

319

320 321 However, it should be noted that the NADIA trial examined the risk of virological failure in 235 PLHIV randomised to DTG, resulting in a small number of treatment failures (n=24), while our study focused on the risk of resistance among people who experienced virological failure. Thus, for DTGbased regimens, NRTI resistance may not substantially affect the risk of treatment failure but still increase the risk of resistance in case of failure. Research on other drug classes<sup>33</sup> has shown that drug regimens with high and low genetic barriers can have similar failure rates but different probabilities of acquiring resistance. Our study contributes new information on DTG resistance in PLHIV receiving different DTG-based ART regimens by examining risk factors for DTG resistance in real-world cohort data from different settings. The cohort collaboration resulted in a large dataset of GRT results in people who experienced virological failure on DTG. Our results are central to informing HIV treatment and monitoring policies in the context of the continued expansion of DTG-based treatment regimens. The pooling of data from diverse routine clinical cohorts also has limitations. The data come from individuals receiving any DTG-based regimen in a wide range of different clinical care settings. We only included people who experienced virological failure and had a GRT, but policies and practices regarding when and for whom GRT is done likely differed between cohorts. In our regression models, we accounted for this heterogeneity between cohorts by including cohort as a random effect, but confounding by cohort may still have affected our results. Further, the personalised approach to ART and HIV care in the European settings will not be generalisable to other settings, particularly low- and middle-income countries. A further limitation of our study is the dominance of HIV subtype B, which was expected considering that our study population is comprised mainly of PLHIV from European countries, where subtype B predominates. More data from people with non-B subtypes are needed, and such a study is ongoing within the framework of the International epidemiology Databases to Evaluate AIDS (IeDEA).<sup>26</sup> In this study, individuals experiencing failure on DTG-based ART are prospectively enrolled in around forty sites across sub-Saharan Africa, South America, and Asia. Furthermore, the WHO plans to launch sentinel surveys of acquired HIV resistance to DTG among people receiving DTG-based ART. 34 We could not assess adherence or drug interactions with rifampicin, which may influence the emergence of DTG resistance.<sup>35</sup> Adherence and rifampicin use were not recorded consistently and comparably in the participating cohorts. In our study population, the DTG-based regimens were too heterogenous to allow investigating DTG resistance outcomes of specific regimens and treatment histories. Lastly, there is growing evidence that mutations outside integrase may confer DTG resistance<sup>36-38</sup>. Our study was based on pol sequences, which did not allow us to investigate these mutations.

323

324

325

326

327

328

329

330331

332

333

334

335336

337

338

339340

The associations we found with DTG resistance, resistance to NRTI backbone drugs, HIV-1 subtype, and unsuppressed virus load have important implications for ensuring the long-term sustainability of ART. While INSTI resistance was rare in our population; it is still a concern. Firstly, the duration of DTG therapy and the duration of viraemia whilst receiving DTG was relatively short in our population: the median time on DTG was less than 2 years and drug resistance might emerge more frequently in settings where individuals remain viraemic for a longer time on DTG regimens. This could happen in resource-limited settings where guidelines recommend not switching from DTGbased therapy unless multiple viral loads >1000 copies/mL have been documented and where delays in regimen switching are common.<sup>39</sup> Secondly, the strong association of DTG resistance with NRTI resistance suggests that the risk of resistance might be higher in people with previous failure on NNRTI-based first-line therapy, among whom the prevalence of NRTI resistance is much higher than in our study population. The WHO guidelines recommend DTG in 1st-, 2nd- and 3rd-line ART. This multiplicity of roles combined with the recycling of drugs and limited access to viral load and drug resistance testing will facilitate the emergence of DTG resistance. Finally, even a relatively low level of acquired DTG resistance in the millions of people receiving DTG-based ART could lead to rising levels of transmitted INSTI resistance, which could affect both treatment and prevention In conclusion, our study underlines the importance of routine viral load monitoring and resistance testing, especially in treatment-experienced people, to prevent resistance both at the individual patient and the population level and thereby ensure the long-term sustainability of ART.

# Figures & tables

**Table 1: Demographics and clinical characteristics in the study population**. People with virological failure on DTG-based ART with available genotypic resistance tests from eight observational HIV cohorts were included in the study. Study participants where clinical data was available for at least one year were considered for analysing risk factors for DTG resistance.

	Analysis of resistance conferring mutations (N=750)	Analysis of risk factors for DTG resistance (N=677)
Sex	7	, ,
Male	522 (69·6%)	463 (68·4%)
Female	228 (30.4%)	214 (31 6%)
Age at DTG Initiation (years)	46 [38 – 54]	47 [38 – 54]
В	444 (59·2%)	403 (59·5%)
Α	56 (7·5%)	53 (7·8%)
C	71 (9·5%)	65 (9 6%)
G	42 (5·6%)	39 (5·8%)
Other*	137 (18-3%)	117 (17 3%)
ART regimen at resistance genotyping		
Combination therapy with ≥3 ARVs	597 (79·6%)	531 (78·4%)
Dual therapy (DTG & Lamivudine)	27(3.6%)	103 (15·2%)
Dual therapy (DTG & other)	107 (14·3%)	25 (3·7%)
Mono therapy	19 (2·5%)	18 (2·7%)
ART duration at DTG initiation (years)	8.7 [2.1 – 17]	9.3 [3.8 – 17]
Missing	7 (0.9%)	7 (1.0%)
ear of DTG initiation	2016 [2015 – 2017]	2016 [2015 – 2017]
ear of genotypic resistance test	2018 [2017 – 2019]	2018 [2017 – 2019]
Availability of additional (prior) GRTs		
Yes	429 (57·2%)	389 (57·5%)
No	321 (42.8%)	288 (42·5%)
Ouration on DTG-based ART (years)	1.6 [0.61 – 3.0]	1.7 [0.71 - 3.1]
exposure to first generation INSTI		
Yes	193 (25·7%)	251 (37·1%)
No	484 (64 5%)	426 (62-9%)
CD4 count at GRT	465 [237 - 718]	483 [250 - 738]
Missing	193 (25·7%)	165 (24·4%)
riral load AUC (of log10 cp/ml during		
OTG based ART)	2.9 [1.6 - 4.6]	2.9 [1.7 – 4.6]
Missing	25 (3·3%)	0 (0%)
Io. of HIV virus load tests per year	2.7 [2.0 - 4.0]	3.0 [2.0 - 4.0]
Missing	20 (2·7%)	0 (0%)
Cohort		
SHCS	118 (15.7%)	109 (16·1%)
AfA	9 (1·2%)	9 (1·3%)
SAC	92 (12·3%)	87 (12.9%)
Aquitaine	215 (28.7%)	195 (28·8%)
ATHENA	66 (8·8%)	64 (9·5%)

CBC	89 (11.9%)	76 (11·2%)	
ICONA	8 (1·1%)	5 (0·7%)	
UK CHIC/UKHDRD	153 (20·4%)	132 (19·5%)	

Numbers (%) and medians [interquartile range] are shown.

\* Other subtypes are comprised as follows: For the analysis of resistance conferring mutations - Unknown, N=69 (9·2%); F, N=21 (2·8%); AG, N=12 (1·6%); AE, N=11 (1·5%); D, N=11 (1·5%); 06\_CPX, N=7 (0·9%); 18\_CPX, N=2 (0·3%); 11\_CPX, N=1 (0·1%); 45\_CPX, N=1 (0·1%); AD, N=1 (0·1%); and H, N=1 (0·1%). For the analysis of risk factors for DTG resistance - Unknown, N=60 (8·9%); F, N=16 (2·4%); AG, N=11 (1·6%); D, N=10 (1·5%); AE, N=8 (1·2%); 06\_CPX, N=6 (0·9%); 18\_CPX, N=2 (0·3%); 11\_CPX, N=1 (0·1%); 45\_CPX, N=1 (0·1%); AD, N=1 (0·1%); and H, N=1 (0·1%).

Abbreviations: ATHENA, the AIDS Therapy Evaluation in the Netherlands cohort; Aquitaine, Agence Nationale de la Recherche sur le SIDA et les hépatites virales (ANRS) CO3 Aquitaine Cohort; ICONA, Italian Cohort of Antiretroviral-Naïve Patients; CBC, Cologne/Bonn Cohort, Germany; SHCS, Swiss HIV Cohort Study; SAC, South Alberta Clinic Cohort, Canada; AfA, Aid for AIDS, South Africa; UK CHIC/UKHDRD, UK Collaborative HIV Cohort (UK CHIC) Study/ UK HIV Drug Resistance Database.




Figure 1: Prevalence of DTG resistance and INSTI DRMs. Genotypic resistance tests of 750 people with genotypic resistance testing on DTG-based ART were analysed using the Stanford resistance algorithm to determine INSTI DRMs and resistance level to DTG. Both major and accessory INSTI DRMs were considered for the number of INSTI DRMs. People with no INSTI DRMs (N = 650, 86.7%), and who are susceptible to DTG (N = 713, 95.1%) are not displayed.





Figure 2: INSTI drug resistance mutations found in 750 people experiencing virologic failure on a DTG-based regimen. Drug resistance mutations were classified as major and accessory according to the Stanford resistance database<sup>27</sup>. Bars are coloured by previous history of first generation INSTIs (raltegravir, elvitegravir).



**Figure 3: Rate ratio for the number of INSTI DRMs**. A negative binomial generalised linear model was fit to the number of major and accessory INSTI DRMs in 750 people with virological failure on DTG-based ART. The plot shows uni- and multivariable point estimates and 95% confidence intervals of rate ratios.

Table 2: Resistance levels to DTG, non-nucleoside reverse transcriptase inhibitors and nucleotide reverse transcriptase inhibitors. The number and percentage of people with corresponding drug resistance levels are given for the entire study population. NRTI resistance level is based on median resistance score to ABC, AZT, XTC and TDF/TAF. NNRTI resistance level is based on median resistance score to EFV, ETR, NVP, and RPV.

	DTG resistance level		
	Susceptible & Potential Low	Low, Intermediate, High	
	(N=721)	(N=29)	
NRTI resistance level			
Susceptible	574 (79·6%)	13 (44.8%)	
Potential Low	14 (1.9%)	2 (6.9%)	
Low	14 (1.9%)	1 (3.4%)	
Intermediate	13 (1.8%)	2 (6.9%)	
High	39 (5·4%)	4 (13.8%)	
RT not covered in GRT	67 (9·3%)	7 (24·1%)	
NNRTI resistance level			
Susceptible	543 (75·3%)	11 (37·9%)	
Potential Low	27 (3·7%)	0 (0%)	
Low	21 (2·9%)	0 (0%)	
Intermediate	39 (5·4%)	4 (13.8%)	
High	24 (3·3%)	7 (24·1%)	
RT not covered in GRT	67 (9·3%)	7 (24·1%)	




Figure 4: Odds ratios for DTG resistance levels with 95% confidence intervals from uni- and multivariable ordinal logistic models for genotypic DTG resistance. Cohorts were included as random effect. DTG resistance levels in people with virological failure on DTG-based ART were assessed using the Stanford resistance algorithm.

## **Authors' contributions**

- Conceptualisation (HFG, JACS, RL, ME, RK), Data curation (TL, SH, SI, HO), Methodology (TL, CS, RK
- 386 ME, JACS), Formal analysis & Validation (TL, RK), Investigation (TL, SH, SI), Project administration (SH,
- 387 SI), Resources (HO, KK, JM, AvS, MS, AAM, JG, CS, GM), Software (TL, KK), Supervision (HFG, JACS, RL,
- 388 ME, RK), Visualisation (TL), Writing original draft (TL, RL, ME, RK), Writing review & editing (All
- 389 authors).

384

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

- 390 TL and RK have directly accessed and verified the underlying data reported in the manuscript. RL, ME
- 391 and RK contributed equally.

### **Declaration of interests**

SMI reports grant funding from NIH NIAAA for the work of ART-CC (payment to institution). AvS reports funding from the Dutch Ministry of Health, Welfare and Sport for the maintenance of the ATHENA database, and grant funding from the European Centre for Disease Prevention and Control (ECDC) (payment to institution). MJG reports honoraria as Ad Hoc member of HIV National Advisory Board from Merck, Gilead Sciences, and ViiV, and a leadership position as Medical Director S Alberta HIV clinic. CAS has received funding from Gilead Sciences, ViiV Healthcare and Janssen-Cilag for membership of Data Safety and Monitoring Committees, Advisory Committees and for preparation of educational material. HFG has received personal fees from Merck, Gilead Sciences, ViiV, GSK, Janssen, Johnson and Johnson and Novartis, as an advisor/consultant or for DSMB membership and has received a travel grant from Gilead. JACS reports funding for research in this publication from NIH NIAAA (payment to institution), UK NIHR (payment to institution), and the University of Bern (payment to institution). RL reports support for research in this publication by the National Institute of Allergy & Infectious Diseases of the National Institutes of Health under award number R01Al152772, and support from the National Institute of Allergy & Infectious Diseases of the National Institutes of Health under award number R01AI167699 for a separate project pertaining to HIV treatment strategies. ME reports funding for research in this publication from the Swiss National Science Foundation (32FP30-18949) and the National Institutes of Health (Cooperative Agreement AI069924 and R01 AI152772-01). RK reports funding for research in this publication from the Swiss National Science Foundation and the National Institute of Allergy & Infectious Diseases of the National Institutes of Health, and reports grant funding from Gilead Sciences. All other authors declare no competing interest.

### **Acknowledgements**

We would like to acknowledge Anthony Hauser, Suraj Balakrishna, and Marius Zeeb for helpful discussions on data analysis. This study was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01Al152772 and the Swiss National Science Foundation (32FP30\_207285, 324730\_207957). The participating cohorts or cohort collaborations were funded by the Swiss National Science Foundation (33CS30 201369) and the Yvonne Jacob Foundation (for the SHCS), the UK Medical Research Council (grant numbers G0000199, G0600337, G0900274, and M004236/1; for the UK Collaborative HIV Cohort), the National Agency for AIDS Research (France REcherche Nord&Sud Sida-hiv Hépatites), the French Agency for Research on AIDS and Viral Hepatitis @Emerging Infectious Diseases (ANRS@MIE) and the CHU de Bordeaux (for the ANRS CO3 Aguitaine-AguiVIH-NA cohort), the Dutch Ministry of Health (for the ATHENA cohort), the German Center for Infection Research (8018704707) (for the CBC), ICONA Foundation is supported by unrestricted grants from BMS, Gilead Sciences, Janssen, MSD and ViiV Healthcare. AFA is supported via IeDEA-SA by the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Division of Cancer Epidemiology and Genetics, National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Diabetes and Digestive and Kidney Diseases and the Fogarty International Center under Award Number U01Al069924. The ART-CC is funded by the US National Institute on Alcohol Abuse and Alcoholism (U01-AA026209). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

# Data sharing statement

- Data underlying the figures and tables reported in this article may be shared following publication of
- 438 this article. Researchers may submit a methodologically sound proposal for the use of these data to
- 439 the corresponding author. De-identified data of individual study participants cannot be made
- available as they are subject to the respective observational HIV cohorts.

### References

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

- 442 1. WHO. Update of recommendations on first- and second-line antiretroviral regimens. Geneva, 443 Switzerland: World Health Organization; WHO. 2019. p. 3.
- 444 2. The Lancet HIV. End resistance to dolutegravir roll-out. Lancet HIV. 2020 Sep 1;7(9):e593.
- Llibre JM, Pulido F, García F, García Deltoro M, Blanco JL, Delgado R. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015;17(1):56–64.
- 447 4. Cottrell ML, Hadzic T, Kashuba ADM. Clinical pharmacokinetic, pharmacodynamic and druginteraction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet.

449	2013;52(11):981–94.
-----	---------------------

- 450 5. Cevik M, Orkin C, Sax PE. Emergent resistance to dolutegravir among instinaive patients on
   451 first-line or second-line antiretroviral therapy: A review of published cases. Open Forum
   452 Infect Dis. 2020;7(6).
- 453 6. Pena MJ, Chueca N, D'Avolio A, Zarzalejos JM, Garcia F. Virological failure in HIV to triple 454 therapy with dolutegravir-based firstline treatment: Rare but possible. Open Forum Infect 455 Dis. 2019;6(1).
- Scherrer AU, Yang W-L, Kouyos RD, Böni J, Yerly S, Klimkait T, et al. Successful Prevention of
   Transmission of Integrase Resistance in the Swiss HIV Cohort Study. J Infect Dis.
   2016;214(3):399–402.
- 459 8. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al.
   460 Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults
   461 with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study.
   462 Lancet. 2013;382(9893):700–8.
- 463 9. Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, et al. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS. 2017;31(10):1425–34.
- Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Efficacy and safety
   of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or
   tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a
   prospective, multicentre, open-label, factorial, randomised, no. Lancet HIV. 2022;1–13.
- Han Y-S, Mesplède T, Wainberg MA. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. Infect Genet Evol. 2016;46:286–91.
- 471 12. Brenner BG, Thomas R, Blanco JL, Ibanescu R-I, Oliveira M, Mesplède T, et al. Development of 472 a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading 473 to cross-resistance to integrase inhibitors. J Antimicrob Chemother. 2016;71(7):1948–53.
- 474 13. Arimide DA, Szojka ZI, Zealiyas K, Gebreegziabxier A, Adugna F, Sasinovich S, et al. Pre-475 Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C 476 Infected Patients in Ethiopia. Viruses. 2022;14(4).
- 477 14. Akil B, Blick G, Hagins DP, Ramgopal MN, Richmond GJ, Samuel RM, et al. Dolutegravir versus 478 placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated 479 substitutions: 48-week results from VIKING-4, a randomized study. Antivir Ther. 480 2015;20(3):343–8.
- 481 15. Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in
  482 antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24483 week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354–62.
- Inzaule SC, Hamers RL, Doherty M, Shafer RW, Bertagnolio S, Rinke de Wit TF. Curbing the
   rise of HIV drug resistance in low-income and middle-income countries: the role of
   dolutegravir-containing regimens. Lancet Infect Dis. 2019;19(7):e246–52.
- 487 17. Boender TS, Smit C, Van Sighem A, Bezemer D, Ester CJ, Zaheri S, et al. AIDS Therapy
  488 Evaluation in the Netherlands (ATHENA) national observational HIV cohort: Cohort profile.
  489 BMJ Open. 2018;8(9).
- Hessamfar M, Colin C, Bruyand M, Decoin M, Bonnet F, Mercié P, et al. Severe morbidity according to sex in the era of combined antiretroviral therapy: The ANRS CO3 aquitaine

according to sex in the era of combined antiretroviral therapy: The ANRS CO3 aquitaine

492 cohort. PLoS On	e. 2014;9(7).
---------------------	---------------

- 493 19. Lepri AC, Phillips AN, Monforte A d'A., Castelli F, Antinori A, De Luca A, et al. When to start 494 highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the 495 ICONA study. AIDS. 2001;15(8):983–90.
- 496 20. Ehren K, Hertenstein C, Kümmerle T, Vehreschild JJ, Fischer J, Gillor D, et al. Causes of death 497 in HIV-infected patients from the Cologne-Bonn cohort. Infection. 2014;42(1):135–40.
- 498 21. Babiker A, Dunn D, Easterbrook P, Fisher M, Gilson R, Johnson M, et al. The creation of a large
  499 UK-based multicentre cohort of HIV-infected individuals: The UK collaborative HIV cohort (UK
  500 CHIC) study. HIV Med. 2004;5(2):115–24.
- 501 22. Scherrer AU, Traytel A, Braun DL, Calmy A, Battegay M, Cavassini M, et al. Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). Int J Epidemiol. 2022;51(1):33-34J.
- 503 23. Beck PL, Gill MJ, Blahey WB, Sutherland LR. HIV-related non-Hodgkin's lymphoma in Calgary. Can J Infect Dis. 1996;7(2):115–20.
- 505 24. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008;5(5):0777–88.
- 508 25. May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, et al. Cohort profile: 509 Antiretroviral therapy cohort collaboration (ART-CC). Int J Epidemiol. 2014;43(3):691–702.
- 510 26. Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, et al. International 511 epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019. BMJ 512 Open. 2020;10(5).
- 513 27. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608–18.
- 515 28. Struck D, Lawyer G, Ternes A-M, Schmit J-C, Bercoff DP. COMET: Adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42(18).
- 517 29. Pineda-Peña A-C, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. Automated 518 subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance 519 evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol. 2013;19:337– 520 48.
- 521 30. Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, et al. Lack of impact of pre-522 existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and 523 treatment outcome. PLoS One. 2017;12(2).
- 524 31. Rolle C-P, Nguyen V, Hinestrosa F, DeJesus E. Virologic outcomes of switching to dolutegravir 525 functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective 526 study of treatment-experienced, patients living with HIV. AIDS Res Ther. 2021;18(1).
- Naeger LK, Harrington P, Komatsu T, Deming D. Effect of dolutegravir functional
   monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant
   patients. Antivir Ther. 2016;21(6):481–8.
- 530 33. Von Wyl V, Yerly S, Böni J, Bü rgisser P, Klimkait T, Battegay M, et al. Emergence of HIV-1 drug 531 resistance in previously untreated patients initiating combination antiretroviral treatment: A 532 comparison of different regimen types. Arch Intern Med. 2007;167(16):1782–90.
- 533 34. WHO. Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving

534 dolutegravir- containing antiretroviral therapy. Geneva; 2022. 535 35. Naidoo A, Naidoo K, Padayatchi N, Dooley KE. Use of integrase inhibitors in HIV-associated 536 tuberculosis in high-burden settings: implementation challenges and research gaps. Lancet 537 HIV. 2022;9(2):e130-8. 538 36. Malet I, Delelis O, Nguyen T, Leducq V, Abdi B, Morand-Joubert L, et al. Variability of the HIV-539 1 32 polypurine tract (32PPT) region and implication in integrase inhibitor resistance. J 540 Antimicrob Chemother. 2019;74(12):3440-4. 541 37. Dekker JG, Klaver B, Berkhout B, Das AT. Mutations in the HIV-1 3-Polypurine Tract Can 542 Confer Dolutegravir Resistance. Antimicrob Agents Chemother. 2022;66(1). 543 Hikichi Y, Groebner JL, Wiengand A, Mellors JW, Kearney MF, Freed EO. Mutations outside 38. 544 integrase lead to high-level resistance to dolutegravir [CROI Abstract 103]. In: Conference on 545 Retroviruses and Opportunistic Infections CROI 2023 Abstract eBook. 2023. 546 39. Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and 547 switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: 548 Collaborative analysis. Lancet HIV. 2015;2(7):e271-8. 549